Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1-year target price among analysts that have covered the stock in the last year is $25.00.

A number of research analysts recently commented on BCYC shares. HC Wainwright restated a "buy" rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a research note on Wednesday, February 26th. B. Riley reduced their price objective on Bicycle Therapeutics from $17.00 to $14.00 and set a "neutral" rating for the company in a research report on Friday, May 2nd. Barclays dropped their price target on shares of Bicycle Therapeutics from $40.00 to $15.00 and set an "overweight" rating on the stock in a research report on Thursday, May 1st. Morgan Stanley set a $17.00 price objective on shares of Bicycle Therapeutics and gave the company an "equal weight" rating in a research note on Monday, May 5th. Finally, JMP Securities reduced their price objective on Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating for the company in a research note on Friday, May 2nd.

Bicycle Therapeutics Price Performance

Shares of Bicycle Therapeutics stock traded down $0.01 on Monday, reaching $8.54. 141,110 shares of the company were exchanged, compared to its average volume of 391,485. The stock's 50 day moving average price is $7.96 and its 200-day moving average price is $11.61. The company has a market cap of $591.43 million, a P/E ratio of -2.60 and a beta of 1.46. Bicycle Therapeutics has a 1-year low of $6.10 and a 1-year high of $28.67.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The company reported ($0.88) EPS for the quarter, missing analysts' consensus estimates of ($0.86) by ($0.02). Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The firm had revenue of $9.98 million during the quarter, compared to analyst estimates of $8.67 million. On average, research analysts predict that Bicycle Therapeutics will post -3.06 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Bicycle Therapeutics

Institutional investors have recently bought and sold shares of the company. Baker BROS. Advisors LP raised its position in shares of Bicycle Therapeutics by 15.8% during the 4th quarter. Baker BROS. Advisors LP now owns 10,885,357 shares of the company's stock valued at $152,395,000 after buying an additional 1,485,397 shares in the last quarter. EntryPoint Capital LLC bought a new stake in Bicycle Therapeutics during the 4th quarter valued at approximately $614,000. Fcpm Iii Services B.V. lifted its position in Bicycle Therapeutics by 47.5% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,452,330 shares of the company's stock valued at $48,333,000 after acquiring an additional 1,112,369 shares during the period. Nan Fung Group Holdings Ltd raised its holdings in Bicycle Therapeutics by 118.3% in the fourth quarter. Nan Fung Group Holdings Ltd now owns 68,943 shares of the company's stock worth $965,000 after buying an additional 37,358 shares during the last quarter. Finally, Springhill Fund Asset Management HK Co Ltd purchased a new stake in shares of Bicycle Therapeutics during the fourth quarter valued at $1,630,000. Hedge funds and other institutional investors own 86.15% of the company's stock.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.